Therefore, EMPA may attenuate TAC-induced cardiac hypertrophy by binding FZD membrane protein, thereby inhibiting the Wnt/β-catenin/TCF7L2 signaling. This evidence concerns the gene TCF7L2 and cardiac hypertrophy.